Although Sanofi (NYSE:SNY) has not always gotten the attention that other major pharmas have drawn for their respective restructuring efforts, Sanofi has changed in some meaningful respects over the past few years. The company could still handle some of its internal operations a bit better, and there are definitely still some challenges to its revenue base, but investors would do well to consider one of the largest pharmaceutical companies in the world for their portfolios.

Investopedia Markets: Explore the best one-stop source for financial news, quotes and insights.

The Good
Sanofi certainly has the scale that it takes to compete in the modern global pharmaceuticals market, as this is not only the fifth-largest drug company, but also one that is well-balanced between markets in the United States and non-U.S. markets. Moreover, the company has a sizable vaccines franchise and has been reinvesting capital in ancillary divisions like consumer health and animal care. (For related reading, see A Primer On The Biotech Sector.)

Sanofi has long had a significant presence in diabetes, thrombosis, cardiovascular, cancer and the aforementioned vaccines. While patent expirations are in the process of decimating four of the company's five largest drug franchises, the pipeline is solid. Drugs like Zaltrap (cancer), Visamerin (embolisms), Lyxuma (diabetes) and sarilumab (rheumatoid arthritis) are all significant potential revenue sources, and the company has an interesting one-two punch in multiple sclerosis. While Sanofi is developing an oral MS compound to compete with drugs from Novartis (NYSE:NVS), Biogen Idec (Nasdaq:BIIB) and Teva (Nasdaq:TEVA), the company also has an interesting infused drug (Lemtrada) in trials as well.

The Bad
Sanofi's pipeline development had some major stumbles at the end of the last decade, as would-be blockbusters like Accomplia (obesity) ended badly. Those setbacks, combined with the unfortunate overlapping patent expirations of drugs like Plavix, Lovenox, Taxotere and Avapro set up the prospect of a nasty patent cliff. As a result, the company has had to rely more on deals - including the large acquisition of Genzyme; a deal that has thus far not really earned its cost.

Worse yet, the company may not be completely past some significant competitive concerns. Sanofi's oral multiple sclerosis drug could be too little too late. Worse, the company's very profitable Lantus insulin franchise (roughly one-quarter of profits) could be under attack soon - Lilly (NYSE:LLY) is trying to develop a biosimilar, while Novo Nordisk (NYSE:NVO) looks to market its own rival product.

Opportunities
To some extent, Sanofi's opportunities lie in fixing up issues that some investors may file under the "Bad" category. For instance, the company is still very weak in biologics and generics, and has no diagnostics offerings to speak of. The company has a deep partnership with Regeneron Pharmaceuticals (Nasdaq:REGN) that could start paying dividends in a few years, but that's not the same as having a strong internal biologics franchise.

Sanofi also has the opportunity to improve its internal efficiency. One of the biggest problems with Sanofi used to be that it held on to low-potential drugs for too long and invested too much R&D in products with small chances of success. In the past three years the company has gotten better about snuffing out low-potential candidates, but more can be done to improve the company's overall R&D efficiency and the time it takes to go from proof-of-concept to human trials. (For related reading, see Buying Into Corporate Research & Development (R&D)).

The Bottom Line
Investors should realize that Total (NYSE:TOT) and L'Oreal (OTCBB:LRLCY) are significant holders that are both looking to eventually sell their stakes (about 10% in total). Even with that overhang, though, these shares look too cheap.

Sanofi's existing drug business and near-term pipeline should be sufficient to drive revenue growth in the range of 2-4% for the next few years. At the same time, there should be a gradual improvement in the free cash flow margin - perhaps even up to the 25% level. Should that all transpire, investors could see nearly 50% returns from this name.

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

At the time of writing, Stephen Simpson did not own shares in any of the companies mentioned in this article.

Related Articles
  1. Stock Analysis

    Analyzing Altria's Return on Equity (ROE) (MO)

    Learn about Altria Group's return on equity (ROE) and analyze net profit margin, asset turnover and financial leverage to determine what is causing its high ROE.
  2. Investing

    What Investors Need to Know About Returns in 2016

    Last year wasn’t a great one for investors seeking solid returns, so here are three things we believe all investors need to know about returns in 2016.
  3. Investing News

    Icahn's Bet on Cheniere Energy: Should You Follow?

    Investing legend Carl Icahn continues to lose money on Cheniere Energy, but he's increasing his stake. Should you follow his lead?
  4. Stock Analysis

    Analyzing Google's Return on Equity (ROE) (GOOGL)

    Learn about Alphabet's return on equity. How has its ROE changed over time, how does it compare to its peers and what factors are driving ROE for the company?
  5. Investing News

    Is Buffett's Bet on Oil Right for You? (XOM, PSX)

    Oil stocks are getting trounced, but Warren Buffett still likes one of them. Should you follow the leader?
  6. Stock Analysis

    The Top 5 Micro Cap Biotechnology Stocks for 2016 (BSTC, OSIR)

    Discover some of the most promising micro-cap biotechnology stocks that investors can consider for their 2016 investment portfolio.
  7. Investing News

    Chipotle Served with Criminal Probe

    Chipotle's beat muted expectations and got a clear bill from the CDC, but it now appears that an investigation into its E.coli breakout has expanded.
  8. Stock Analysis

    Analyzing Sprint Corp's Return on Equity (ROE) (S)

    Learn about Sprint's return on equity. Find out why its ROE is negative and how asset turnover and financial leverage impact ROE relative to Sprint's peers.
  9. Stock Analysis

    Why Alphabet is the Best of the 'FANGs' for 2016

    Alphabet just impressed the street, but is it the best FANG stock?
  10. Investing News

    A 2016 Outlook: What January 2009 Can Teach Us

    January 2009 and January 2016 were similar from an investment standpoint, but from a forward-looking perspective, they were very different.
RELATED FAQS
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>
COMPANIES IN THIS ARTICLE
Trading Center